Literature DB >> 33571003

The clinical effectiveness of reconstructing 18F-sodium fluoride PET/CT bone using Bayesian penalized likelihood algorithm for evaluation of metastatic bone disease in obese patients.

Sharjeel Usmani1,2,3, Najeeb Ahmed4, Gopinath Gnanasegaran5, Rashid Rasheed1, Fahad Marafi2, Mashari Alnaaimi1, Mohammad Omar1, Ahmed Musbah1, Fareeda Al Kandari1, Stijn De Schepper3,6, Tim Van den Wyngaert3,6.   

Abstract

OBJECTIVE: A new Bayesian penalized likelihood reconstruction algorithm for positron emission tomography (PET) (Q.Clear) is now in clinical use for fludeoxyglucose (FDG) PET/CT. However, experience with non-FDG tracers and in special patient populations is limited. This pilot study aims to compare Q.Clear to standard PET reconstructions for 18F sodium fluoride (18F-NaF) PET in obese patients.
METHODS: 30 whole body 18F-NaF PET/CT scans (10 patients with BMI 30-40 Kg/m2 and 20 patients with BMI >40 Kg/m2) and a NEMA image quality phantom scans were analyzed using ordered subset expectation maximization (OSEM) and Q.Clear reconstructions methods with B400, 600, 800 and 1000. The images were assessed for overall image quality (IQ), noise level, background soft tissue, and lesion detectability, contrast recovery (CR), background variability (BV) and contrast-to-noise ratio (CNR) for both algorithms.
RESULTS: CNR for clinical cases was higher for Q.Clear than OSEM (p < 0.05). Mean CNR for OSEM was (21.62 ± 8.9), and for Q.Clear B400 (31.82 ± 14.6), B600 (35.54 ± 14.9), B800 (39.81 ± 16.1), and B1000 (40.9 ± 17.8). As the β value increased the CNR increased in all clinical cases. B600 was the preferred β value for reconstruction in obese patients. The phantom study showed Q.Clear reconstructions gave lower CR and lower BV than OSEM. The CNR for all spheres was significantly higher for Q.Clear (independent of β) than OSEM (p < 0.05), suggesting superiority of Q.Clear.
CONCLUSION: This pilot clinical study shows that Q.Clear reconstruction algorithm improves overall IQ of 18F-NaF PET in obese patients. Our clinical and phantom measurement results demonstrate improved CNR and reduced BV when using Q.Clear. A β value of 600 is preferred for reconstructing 18F-NaF PET/CT with Q.Clear in obese patients. ADVANCES IN KNOWLEDGE: 18F-NaF PET/CT is less susceptible to artifacts induced by body habitus. Bayesian penalized likelihood reconstruction with18F-NaF PET improves overall IQ in obese patients.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33571003      PMCID: PMC8010560          DOI: 10.1259/bjr.20210043

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  23 in total

Review 1.  A systematic review of the factors affecting accuracy of SUV measurements.

Authors:  Michael C Adams; Timothy G Turkington; Joshua M Wilson; Terence Z Wong
Journal:  AJR Am J Roentgenol       Date:  2010-08       Impact factor: 3.959

2.  Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic.

Authors:  H Svanholm; H Starklint; H J Gundersen; J Fabricius; H Barlebo; S Olsen
Journal:  APMIS       Date:  1989-08       Impact factor: 3.205

3.  (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging.

Authors:  M Beheshti; F M Mottaghy; F Paycha; F F F Behrendt; T Van den Wyngaert; I Fogelman; K Strobel; M Celli; S Fanti; F Giammarile; B Krause; W Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-23       Impact factor: 9.236

4.  Standard OSEM vs. regularized PET image reconstruction: qualitative and quantitative comparison using phantom data and various clinical radiopharmaceuticals.

Authors:  Judit Lantos; Erik S Mittra; Craig S Levin; Andrei Iagaru
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

5.  Diagnostic Challenge of Staging Metastatic Bone Disease in the Morbidly Obese Patients: A Primary Study Evaluating the Usefulness of 18F-Sodium Fluoride (NaF) PET-CT.

Authors:  Sharjeel Usmani; Fahad Marafi; Najeeb Ahmed; Abdulredha Esmail; Fareeda Al Kandari; Tim Van den Wyngaert
Journal:  Clin Nucl Med       Date:  2017-11       Impact factor: 7.794

6.  A clinical evaluation of the impact of the Bayesian penalized likelihood reconstruction algorithm on PET FDG metrics.

Authors:  Delphine Vallot; Olivier Caselles; Leonor Chaltiel; Anthony Fernandez; Erwan Gabiache; Lawrence Dierickx; Slimane Zerdoud; Mathilde Bauriaud; Frédéric Courbon
Journal:  Nucl Med Commun       Date:  2017-11       Impact factor: 1.690

7.  Effects of injected dose, BMI and scanner type on NECR and image noise in PET imaging.

Authors:  Tingting Chang; Guoping Chang; Steve Kohlmyer; John W Clark; Eric Rohren; Osama R Mawlawi
Journal:  Phys Med Biol       Date:  2011-07-26       Impact factor: 3.609

8.  Novel weight-based dose threshold for 18F-NaF PET-CT imaging using advanced PET-CT systems: a potential tool for reducing radiation burden.

Authors:  Fahad Marafi; Abdulreda Esmail; Rashid Rasheed; Fareeda Alkandari; Sharjeel Usmani
Journal:  Nucl Med Commun       Date:  2017-09       Impact factor: 1.690

9.  Impact of time-of-flight and point-spread-function in SUV quantification for oncological PET.

Authors:  Elena Prieto; Inés Domínguez-Prado; María José García-Velloso; Iván Peñuelas; José Ángel Richter; Josep Maria Martí-Climent
Journal:  Clin Nucl Med       Date:  2013-02       Impact factor: 7.794

10.  Phantom and Clinical Evaluation of the Bayesian Penalized Likelihood Reconstruction Algorithm Q.Clear on an LYSO PET/CT System.

Authors:  Eugene J Teoh; Daniel R McGowan; Ruth E Macpherson; Kevin M Bradley; Fergus V Gleeson
Journal:  J Nucl Med       Date:  2015-07-09       Impact factor: 10.057

View more
  1 in total

1.  Can Q.Clear reconstruction be used to improve [68 Ga]Ga-DOTANOC PET/CT image quality in overweight NEN patients?

Authors:  Lucia Zanoni; Giulia Argalia; Emilia Fortunati; Claudio Malizia; Vincenzo Allegri; Diletta Calabrò; Simona Civollani; Davide Campana; Stefano Fanti; Valentina Ambrosini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-25       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.